An assistant's crawler fetches the page once, without running JavaScript, and reads the text, the structured data and the links. This is that view of omeicos.com, from the copy the scanner kept.
characters of text without JavaScript
structured data for the business
of 3 AI crawlers turned away at the edge
Title: OMEICOS · language en-US. First 1,800 of 3,065 characters:
OMEICOS Skip to content COMPANY OVERVIEW LEADERSHIP BOARD INVESTORS TIMELINE OUR SCIENCE INTRODUCTION Mode of Action SCIENCE LIBRARY PIPELINE OVERVIEW PMD-OPTION study OMT-28 NEWS & EVENTS TEAM & CAREERS LEGAL NOTICE DISCLAIMER DATA PROTECTION HOME OMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases Following Positive EOP2 Meeting with the FDA Targeting Both Inflammation and Mitochondrial Dysfunction to Address Diseases With High Unmet Need OMEICOS is focused on developing therapies that have the potential for a significant impact on cardiovascular, inflammatory and mitochondrial diseases with high unmet need. Our pipeline is based on our proprietary approach to target one of nature’s most important cell-protective pathways and industry-leading knowledge of omega-3 fatty acid metabolism and biology. Our lead compound OMT-28 has successfully concluded the Phase 2a proof-of-concept study in Primary Mitochondrial Disease (PMD). The „PMD-OPTION“ study demonstrated OMT-28’s therapeutic potential to improve the physical condition in patients with PMD based on significant recovery of the impaired mitochondrial function in the responding patients. The study also further underscored the excellent safety and tolerability profile of OMT-28, which has been evaluated in more than 190 individuals to date. Subsequently, the program has received strong endorsement from the U.S. Food and Drug Administration (FDA) in an End-of-Phase 2 (EOP2) meeting and as a result is now positioned to advance directly into a pivotal Phase 3 study. OMT-28 had previously been evaluated in a double-blinded, placebo-controlled, multi-center Phase 2 clinical trial in patients suffering from atrial fibrillation. In this study, OMT-28 demonstrated an excellent safety and tolerability profile,
| A business type in JSON-LD | no |
| Name | no |
| Telephone | no |
| Address | no |
| Opening hours | no |
| Menu or price list | nothing |
| Cuisine in structured data | no |
| JSON-LD blocks | 0 |
No booking or ordering link found. An agent has nothing to act on.
Everything here comes from one fetch of the homepage as a crawler; the report turns it into a score and fixes, with a kit to paste.